Celgene (CELG)

Starrob posted this on the Celgene board. I’m reposting it here for your interest:

'The first look at Celgene’s (CELG) experimental Crohn’s disease drug GED-0301 is impressive and explains why company executives have been so upbeat on the drug since acquiring it last spring for big bucks. As a pill, GED-031 (also known as mongersen) has the potential to become a preferred Crohn’s therapy over injectable drugs, most prominently, Abbvie’s (ABBV) top-selling Humira.

Little wonder then that Celege was gaining 2.4% on Monday to $95.24.

In a phase II study of 160 patients with active Crohn’s disease, a high dose of mongersen (160 mg/day) demonstrated a statistically significant remission rate of 65% compared to 9.5% for a placebo, measured after two weeks of treatment. Remission is defined as a Crohn’s Disease Activity Index (CDAI) score of less than 150, maintained for at least two weeks. The response rate for the high dose of mongersen (CDAI reduction of at least 100 points after 28 days) was 72% compared to 17% for placebo, also statistically significant.

Mongersen safety profile looks relatively clean, with most adverse events related to complications of Crohn’s disease. ’